S095018
Total Payments
$15,400
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $15,400 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,400 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| "Phase 1b/2 platform study of select immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC)" | Servier BioInnovation | $15,400 | 0 |
Top Doctors Receiving Payments for S095018
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Canton, OH | $15,400 | 6 |
Ad
Manufacturing Companies
- Servier BioInnovation $15,400
Product Information
- Type Drug
- Total Payments $15,400
- Total Doctors 0
- Transactions 6
About S095018
S095018 is a drug associated with $15,400 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Servier BioInnovation.
Payment data is available from 2024 to 2024. In 2024, $15,400 was paid across 6 transactions to 0 doctors.
The most common payment nature for S095018 is "Unspecified" ($15,400, 100.0% of total).
S095018 is associated with 1 research study, including ""Phase 1b/2 platform study of select immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC)"" ($15,400).